UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Impact of Stochastic Volatility on Initial Margin and MVA for Interest Rate Derivatives

Applied mathematical finance., 2022-03, Vol.29 (2), p.141-179

2022

Volltextzugriff (PDF)

Are blastocyst aneuploidy rates different between fertile and infertile populations?

Fertility and sterility, 2016-09, Vol.106 (3), p.e321-e321

2016

Volltextzugriff (PDF)

How often do patients undergoing IVF-PGS for sex selection actually have a choice?

Fertility and sterility, 2016-09, Vol.106 (3), p.e159-e159

2016

Volltextzugriff (PDF)

Does euploid embryo ranking by trophectoderm cell mitochondrial dna content correspond with ranking by blastocyst morphology within an individual patient’s cohort of blastocysts?

Fertility and sterility, 2016-09, Vol.106 (3), p.e18-e18

2016

Volltextzugriff (PDF)

Recovery of knee range of motion after total knee arthroplasty in the first postoperative weeks: poor recovery can be detected early

Musculoskeletal surgery, 2019-12, Vol.103 (3), p.289-297

2019

Volltextzugriff (PDF)

Does blastocyst morphology predict pregnancy outcomes in euploid single embryo transfers?

Fertility and sterility, 2015-09, Vol.104 (3), p.e276-e276

2015

Volltextzugriff (PDF)

Progesterone supplementation for luteal phase support in non-assisted reproductive technology treatments - prevalence of use and practice patterns among infertility specialists

Fertility and sterility, 2016-09, Vol.106 (3), p.e326-e327

2016

Volltextzugriff (PDF)

Effect of BMI on live birth rates in euploid frozen single embryo transfers

Fertility and sterility, 2016-09, Vol.106 (3), p.e265-e265

2016

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Renal Impairment

Journal of hepatology, 2016, Vol.64 (2), p.S405-S406

2016

Volltextzugriff (PDF)

ABT-493 and ABT-530 Combination Demonstrated Minimal Potential for CYP-Mediated Drug-Drug Interactions

Journal of hepatology, 2016, Vol.64 (2), p.S405-S405

2016

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Hepatic Impairment

Journal of hepatology, 2016, Vol.64 (2), p.S406-S406

2016

Volltextzugriff (PDF)

P0855 : Pharmacokinetics of ABT-493 and ABT-530 is similar in healthy caucasian, Chinese, and Japanese adult subjects

Journal of hepatology, 2015-04, Vol.62, p.S660-S661

2015

Volltextzugriff (PDF)

Stakeholders’ perspectives on energy related Smart City technologies: POCITYF’s standpoint

IOP conference series. Earth and environmental science, 2021-10, Vol.863 (1), p.12012

2021

Volltextzugriff (PDF)

Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies

Journal of hepatology, 2016, Vol.64 (2), p.S809-S809

2016

Volltextzugriff (PDF)

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S33-S33

2017

Volltextzugriff (PDF)

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Journal of hepatology, 2017, Vol.66 (1), p.S83-S84

2017

Volltextzugriff (PDF)

High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I)

Journal of hepatology, 2016, Vol.64 (2), p.S757-S757

2016

Volltextzugriff (PDF)

100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients with Genotypes 4, 5, or 6 Infection (Surveyor-I)

Journal of hepatology, 2016, Vol.64 (2), p.S758-S758

2016

Volltextzugriff (PDF)

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

Journal of hepatology, 2016, Vol.64 (2), p.S409-S410

2016

Volltextzugriff (PDF)

High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection

Journal of hepatology, 2016, Vol.64 (2), p.S768-S768

2016

Volltextzugriff (PDF)

Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection

Journal of hepatology, 2016, Vol.64 (2), p.S292-S292

2016

Volltextzugriff (PDF)

High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study

Journal of hepatology, 2016, Vol.64 (2), p.S160-S161

2016

Volltextzugriff (PDF)

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection

Journal of hepatology, 2016, Vol.64 (2), p.S186-S186

2016

Volltextzugriff (PDF)

100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis

Journal of hepatology, 2016, Vol.64 (2), p.S208-S208

2016

Volltextzugriff (PDF)

Quantifying biological nitrogen fixation of agroforestry shrub species using 15N dilution techniques under greenhouse conditions

Agroforestry systems, 2014-08, Vol.88 (4), p.607-617

2014

Volltextzugriff (PDF)

1 – 25 von 838

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(601)
Mit Volltextzugriff
(686)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(84)
Biological And Medical Sciences
(52)
Male
(48)
Female
(43)
Medical Sciences
(40)
Social Sciences
(40)
Middle Aged
(30)
Animals
(28)
Internal Medicine
(28)
Business & Economics
(25)
Economics
(23)
Medicine
(20)
Adult
(19)
Medicine & Public Health
(19)
Aged
(18)
Capital Markets & Securities Law & Regulation
(18)
Gastroenterology And Hepatology
(17)
Studies
(17)
Fundamental And Applied Biological Sciences. Psychology
(14)
Obstetrics And Gynecology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

The Impact of Stochastic Volatility on Initial Margin and MVA for Interest Rate Derivatives

Are blastocyst aneuploidy rates different between fertile and infertile populations?

How often do patients undergoing IVF-PGS for sex selection actually have a choice?

Does euploid embryo ranking by trophectoderm cell mitochondrial dna content correspond with ranking by blastocyst morphology within an individual patient’s cohort of blastocysts?

Recovery of knee range of motion after total knee arthroplasty in the first postoperative weeks: poor recovery can be detected early

Does blastocyst morphology predict pregnancy outcomes in euploid single embryo transfers?

Progesterone supplementation for luteal phase support in non-assisted reproductive technology treatments - prevalence of use and practice patterns among infertility specialists

Effect of BMI on live birth rates in euploid frozen single embryo transfers

Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Renal Impairment

ABT-493 and ABT-530 Combination Demonstrated Minimal Potential for CYP-Mediated Drug-Drug Interactions

Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Hepatic Impairment

P0855 : Pharmacokinetics of ABT-493 and ABT-530 is similar in healthy caucasian, Chinese, and Japanese adult subjects

Stakeholders’ perspectives on energy related Smart City technologies: POCITYF’s standpoint

Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I)

100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients with Genotypes 4, 5, or 6 Infection (Surveyor-I)

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection

Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection

High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection

100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis

Quantifying biological nitrogen fixation of agroforestry shrub species using 15N dilution techniques under greenhouse conditions

Aktive Filter

Suchergebnisse filtern